Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

TCT Daily: Cypher More Effective for Long Lesions

TCT Daily: Cypher More Effective for Long Lesions The rate of in‐segment restenosis was 77% lower among patients with long native coronary lesions treated with sirolimus‐eluting stents (Cypher, Cordis/Johnson & Johnson, Miami Lakes, FL) compared with patients treated with paclitaxel‐eluting stents (Taxus, Boston Scientific, Natick, MA). Results of the LONG‐DES II trial were presented by Seung‐Jung Park, MD, an interventional cardiologist at the University of Ulsan College of Medicine in South Korea. The LONG‐DES II trial enrolled 500 patients from five clinical centers in South Korea. Patients had coronary lesions at least 25 mm in length. They were randomized in a one‐to‐one ratio to receive either sirolimus‐eluting stents or paclitaxel‐eluting stents. At 6‐month follow‐up, patients in the sirolimus‐eluting stent arm had a 3.3% rate of in‐segment restenosis compared with 14.6% in the paclitaxel‐eluting stent group (P < 0.0001) ( Figure 1 ). 1 Minimal lumen diameter and diameter stenosis were both significantly better in the sirolimus‐eluting stent group at 6‐month angiographic follow‐up. In‐segment minimal lumen diameter was 2.13 mm in the sirolimus‐eluting stent group and 1.87 mm in the paclitaxel‐eluting stent group (P < 0.001). Diameter stenosis in‐segment was 20.1% in the sirolimus‐eluting stent group and 31.4% in the paclitaxel‐eluting stent group (P < 0.001). Clinical Outcomes Clinical follow‐up was performed at 9 months. Rates of death and myocardial infarction did not differ significantly between the two groups. However, target lesion revascularization was significantly lower in the sirolimus‐eluting stent group at 2.4%, compared with 7.2% in the paclitaxel‐eluting stent group (P = 0.012). Similarly, target vessel revascularization was 3.2% in the sirolimus‐eluting stent group vs. 7.6% in the paclitaxel‐eluting stent group (P = 0.03). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

TCT Daily: Cypher More Effective for Long Lesions

Journal of Interventional Cardiology , Volume 20 (1) – Feb 1, 2007
Download PDF
1 page

Loading next page...
 
/lp/wiley/tct-daily-cypher-more-effective-for-long-lesions-ra6iyZS93j

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wiley
Copyright
Copyright © 2007 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1111/j.1540-8183.2007.00233.x
pmid
17300398
Publisher site
See Article on Publisher Site

Abstract

The rate of in‐segment restenosis was 77% lower among patients with long native coronary lesions treated with sirolimus‐eluting stents (Cypher, Cordis/Johnson & Johnson, Miami Lakes, FL) compared with patients treated with paclitaxel‐eluting stents (Taxus, Boston Scientific, Natick, MA). Results of the LONG‐DES II trial were presented by Seung‐Jung Park, MD, an interventional cardiologist at the University of Ulsan College of Medicine in South Korea. The LONG‐DES II trial enrolled 500 patients from five clinical centers in South Korea. Patients had coronary lesions at least 25 mm in length. They were randomized in a one‐to‐one ratio to receive either sirolimus‐eluting stents or paclitaxel‐eluting stents. At 6‐month follow‐up, patients in the sirolimus‐eluting stent arm had a 3.3% rate of in‐segment restenosis compared with 14.6% in the paclitaxel‐eluting stent group (P < 0.0001) ( Figure 1 ). 1 Minimal lumen diameter and diameter stenosis were both significantly better in the sirolimus‐eluting stent group at 6‐month angiographic follow‐up. In‐segment minimal lumen diameter was 2.13 mm in the sirolimus‐eluting stent group and 1.87 mm in the paclitaxel‐eluting stent group (P < 0.001). Diameter stenosis in‐segment was 20.1% in the sirolimus‐eluting stent group and 31.4% in the paclitaxel‐eluting stent group (P < 0.001). Clinical Outcomes Clinical follow‐up was performed at 9 months. Rates of death and myocardial infarction did not differ significantly between the two groups. However, target lesion revascularization was significantly lower in the sirolimus‐eluting stent group at 2.4%, compared with 7.2% in the paclitaxel‐eluting stent group (P = 0.012). Similarly, target vessel revascularization was 3.2% in the sirolimus‐eluting stent group vs. 7.6% in the paclitaxel‐eluting stent group (P = 0.03).

Journal

Journal of Interventional Cardiology – Wiley

Published: Feb 1, 2007

There are no references for this article.